US phase I trial of an encapsulated cell therapy product [NovaCaps] for delaying the accumulation of malignant ascites fluid in patients with peritoneal cancer
Latest Information Update: 24 Mar 2015
Price :
$35 *
At a glance
- Drugs Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Ifosfamide
- Indications Malignant ascites; Peritoneal cancer
- Focus Adverse reactions
- 24 Mar 2015 New trial record